• Clinical Technology
  • Adult Immunization
  • Hepatology
  • Pediatric Immunization
  • Screening
  • Psychiatry
  • Allergy
  • Women's Health
  • Cardiology
  • Pediatrics
  • Dermatology
  • Endocrinology
  • Pain Management
  • Gastroenterology
  • Infectious Disease
  • Obesity Medicine
  • Rheumatology
  • Nephrology
  • Neurology
  • Pulmonology

7 New Drugs Approved for Primary Care: Q1 2022

Slideshow

At the close of the first quarter of a new year, Patient Care Online has compiled a list of 7 new FDA-approved drugs for conditions that are often seen in primary care. Scroll through the slides below to find details on a new oral solution of amlodipine; the first and only FDA-approved, once-daily amphetamine transdermal patch for the treatment of attention deficit hyperactivity disorder; and 5 more.

Related Videos
"Vaccination is More of a Marathon than a Sprint"
Vaccines are for Kids, Booster Fatigue, and Other Obstacles to Adult Immunization
Tezepelumab Significantly Reduced Exacerbations in Patients with Severe Asthma, Respiratory Comorbidities
Document COVID Sequelae and Primary Care: An Interview with Samoon Ahmad, MD
Related Content
FDA Approves Updated Indication Statement for Upadacitinib in Inflammatory Bowel Disease Treatment / Image credit: ©unlimit3d/AdobeStock

FDA Approves Updated Indication Statement for Upadacitinib in Inflammatory Bowel Disease Treatment

Sydney Jennings
October 14th 2025
Article

FDA approves updated indication for upadacitinib in ulcerative colitis and Crohn disease treatment, allowing use after one systemic therapy when TNF blockers are clinically inadvisable.

2025 AAD Atopic Dermatitis Update: Linda Stein Gold, MD, on New Topical and Biologic Therapies

2025 AAD Atopic Dermatitis Update: Linda Stein Gold, MD, on New Topical and Biologic Therapies

Linda Stein Gold, MD;Sydney Jennings
August 25th 2025
Podcast

Linda Stein Gold, MD, reviews AAD’s 2025 updates on new topical and biologic options for adult atopic dermatitis.

FDA Clears First Blood Test to Rule Out Alzheimer-Related Pathology in Primary Care / image credit ©muhammed/stock.adobe.com

FDA Clears First Blood Test to Rule Out Alzheimer-Related Pathology in Primary Care

Grace Halsey
October 13th 2025
Article

Roche's Elecsys pTau181 test has a 97.9% negative predictive value to rule out amyloid pathology, which will improve referral decisions and expedite treatment.

The Weekly Dose: Pediatric Vaccine Safety, Atopic Dermatitis, Dementia Risk, and Maternal Depression

The Weekly Dose: Pediatric Vaccine Safety, Atopic Dermatitis, Dementia Risk, and Maternal Depression

Sydney Jennings
August 7th 2025
Podcast

Insights on atopic dermatitis treatment preferences, the safety of childhood vaccines, maternal depression’s effect on parenting, and more.

FDA Expands Indication for Roflumilast Treat Atopic Dermatitis in Children Ages 2 to 5 Image Courtesy of Arcutis

FDA Expands Indication for Roflumilast to Treat Atopic Dermatitis in Children Aged 2 to 5 Years

Grace Halsey
October 6th 2025
Article

The approval of roflumilast 0.05% provides a steroid-free, once-daily treatment option for safe and effective long-term management of pediatric eczema.

FDA Quietly Approves Another Generic Formulation of Abortion Drug Mifepristone image credit ©Casimiro/stock.adobe.com

FDA Quietly Approves Another Generic Formulation of Abortion Drug Mifepristone

Grace Halsey
October 3rd 2025
Article

FDA did not announce the September 30 approval, which took place despite strong partisan opposition and during an uncompleted review of the drug's safety.

© 2025 MJH Life Sciences

All rights reserved.